Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Naproxen
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Gastrointestinal=== As with other non-[[COX-2]] selective NSAIDs, naproxen can cause [[gastrointestinal problem]]s, such as heartburn, constipation, diarrhea, ulcers and stomach bleeding.<ref>{{cite web | url = https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000526 | archive-url = https://web.archive.org/web/20100722112536/http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000526 | archive-date = 22 July 2010 | date = 1 September 2008 | title = Naproxen | website = PubMed Health }}</ref> Naproxen should be taken orally with, or just after food, to decrease the risk of [[Gastrointestinal tract|gastrointestinal]] side effects.<ref name="NHS_2022">{{cite web |url=https://www.nhs.uk/medicines/naproxen/how-and-when-to-take-naproxen/ |title= How to take it|author=<!--Not stated--> |date=20 January 2022 |website=NHS.Gov |publisher= |quote=}}</ref> Persons with a history of [[ulcers]] or [[inflammatory bowel disease]] should consult a doctor before taking naproxen.<ref name="NHS_2022"/> In U.S. markets, naproxen is sold with [[boxed warning]]s about the risk of gastrointestinal ulceration or bleeding.<ref name=drugs/> Naproxen poses an intermediate risk of stomach ulcers compared with [[ibuprofen]], which is low-risk, and [[indometacin]], which is high-risk.<ref>{{cite journal | vauthors = Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY | title = Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach | journal = Annals of the Rheumatic Diseases | volume = 63 | issue = 7 | pages = 759β766 | date = July 2004 | pmid = 15194568 | pmc = 1755051 | doi = 10.1136/ard.2003.015925 }}</ref> To reduce stomach ulceration risk, it is often combined with a [[proton-pump inhibitor]] (a medication that reduces [[stomach acid]] production) during long-term treatment of those with pre-existing stomach ulcers or a history of developing stomach ulcers while on NSAIDs.<ref name="AMH">{{cite book | veditors = Rossi S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref><ref name="BNF">{{cite book | isbn = 978-0-85711-084-8 | title = British National Formulary (BNF) | last1 = Joint Formulary Committee | year = 2013 | publisher = Pharmaceutical Press | location = London, UK | edition = 65 | pages = [https://archive.org/details/bnf65britishnati0000unse/page/665 665, 673] | url = https://archive.org/details/bnf65britishnati0000unse/page/665 }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)